NCT01896583 - A Phase 2 Pilot Study to Assess ASP7147 in Patients With Diarrhea Predominant Irritable Bowel Syndrome (IBS-D) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 2013

Primary Completion Date

March 31, 2014

Study Completion Date

July 31, 2014

Conditions

Diarrhea Predominant Irritable Bowel Syndrome

Interventions

DRUG

ASP7147

300 mg, tablet, twice per day for 4 weeks oral

DRUG

Placebo

Trial Locations (13)

PMG Research of Winston-Salem, LLC, Winston-Salem

San Marcus Research Clinic Inc, Miami

Suncoast Research Group, LLC, Miami

Meridien Research, St. Petersburg

Remington-Davis, Inc., Columbus

Sundance Clinical Research, St Louis

DCT - Stone Oak, LLC dba Discovery Clinical Trials, San Antonio

Elite Clinical Studies, Phoenix

OM Medical, Las Vegas

Shahram Jacobs, M.D., Inc., Encino

Grossmont Center for Clinical Research, La Mesa

Probe Clinical Research Group, Santa Ana

MedVadis Research Corporation, Watertown

All Listed Sponsors

lead

Seldar Pharma, Inc.

INDUSTRY